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OBJECTIVES We aimed to evaluate the benefits of the glycoprotein (GP) IIb/IIIa antagonist, eptifibatide,
after patients with acute coronary syndromes (ACS) were admitted to hospitals that approach
revascularization for ACS through early transfer to tertiary referral centers.
BACKGROUND Across a variety of hospital settings, GP IIb/IIIa inhibition, after patients were admitted to
the hospital for non-ST segment elevation ACS, is associated with a reduction in death or
myocardial infarction (MI) before and during a percutaneous coronary intervention.
METHODS The outcomes of 429 patients from 153 sites in the Platelet glycoprotein IIb/IIIa in unstable
angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, who were
transferred during study drug infusion (“transfer patients”), were compared with those of
1,987 patients who either remained in the hospital at those sites or were transferred after
study drug termination (“nontransfer patients”).
RESULTS The baseline characteristics of transfer and nontransfer patients were similar. Patients
receiving eptifibatide were transferred less frequently than those receiving placebo (16% vs.
20%, p 5 0.014). Transfer patients underwent more procedures and experienced a greater
30-day incidence of death or MI, as compared with nontransfer patients (21% vs. 12%, p 5
0.001). Eptifibatide was associated with a reduction in death or MI through 30 days,
independent of transfer status (2.5% absolute reduction), as well as for those transferred (5.5%
absolute reduction).
CONCLUSIONS For patients with ACS admitted to community hospitals, eptifibatide is associated with a
reduced need for transfer and improved clinical outcomes. (J Am Coll Cardiol 2001;37:
492–8) © 2001 by the American College of Cardiology
Disruption of atherosclerotic plaque and subsequent platelet
aggregation are common in both acute coronary syndromes
(ACS) and percutaneous coronary interventions (PCI) (1–
3). Randomized trials have shown that platelet glycoprotein
(GP) IIb/IIIa receptor inhibition reduces the ischemic com-
plications of percutaneous revascularization for unstable angina
(4–7). Other trials have shown that the benefits of GP
blockade are in effect during the period before PCI (5,8,9).
The Platelet glycoprotein IIb/IIIa in unstable angina:
Receptor Suppression Using Integrilin Therapy (PUR-
SUIT) trial was designed to test whether potent platelet
inhibition with eptifibatide would reduce death and myo-
cardial infarction (MI) in patients with ACS. Among
PURSUIT patients, those undergoing revascularization
within the first 72 h experienced a 5.1% absolute reduction
in events with the use of eptifibatide, and GP IIb/IIIa
inhibition reduced the frequency of the composite end point
both before and after the procedure (9).
Although the data supporting the use of GP IIb/IIIa
antagonists during ACS are simple to extrapolate for centers
with interventional facilities, the data are less clear for
centers without such facilities (75% of U.S. hospitals and an
even greater percentage worldwide), many of which employ
a strategy of revascularization through transfer to tertiary
referral centers. For these centers, the benefits of GP
IIb/IIIa administration before a decision is made regarding
revascularization or documentation of a percutaneously
approachable lesion must be weighed against potential
complications associated with use of the drug during patient
transfer, as well as in a broader spectrum of the patient
population.
In PURSUIT, a percentage of patients were transferred
to tertiary care centers because of worsening clinical status
or for additional diagnostic or interventional procedures.
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This study explores the strategy of therapy and early transfer
to referral centers of patients with ACS initially admitted to
nontertiary care centers, and it specifically examines the
treatment effect of eptifibatide within this strategy. We
hypothesized that eptifibatide administration might have
incremental benefit in patients subsequently transferred
because of their high risk profiles and the likelihood of a
subsequent coronary intervention, without the increased
complications associated with pretransfer use.
METHODS
Patient group. The study design and results of PURSUIT
have been published previously (9). Patients presenting with
ischemic chest discomfort at rest lasting $10 min within the
previous 24 h were eligible for randomization, provided they
had either creatine kinase, myocardial band fraction (CK-
MB) elevation or electrocardiographic (ECG) evidence of
ST segment or T-wave deviation. Patients were randomized
to receive an intravenous bolus and infusion of placebo, a
bolus of 180 mg/kg body weight followed by an infusion of
1.3 mg/kg per min of eptifibatide or a bolus of 180 mg/kg
followed by an infusion of 2.0 mg/kg per min of eptifibatide.
The study drug was infused for 72 h or until hospital
discharge. Aspirin and intravenous or subcutaneous heparin
were recommended for all patients. During eptifibatide
administration, fibrinolytic therapy and other GP IIb/IIIa
inhibitors were prohibited. All other treatment decisions,
including medical therapy, hospital transfer, cardiac cathe-
terization and revascularization, were left the discretion of
the physician caring for the patient. If transfer to a tertiary
referral center was desired, continuation of the study drug
was recommended. If catheterization and angioplasty were
performed, continuation of the drug for 24 h after the
procedure, up to a maximum of 96 h, was also recom-
mended.
The primary end point of PURSUIT was the composite
of death from any cause or nonfatal MI within 30 days.
Myocardial infarction was defined as new chest pain and ST
segment elevation within 18 h of enrollment, new or repeat
CK-MB elevation above the upper limit of normal after
18 h, CK-MB elevation above three times the upper limit of
normal after PCI and CK-MB elevation above five times
the upper limit of normal after coronary artery bypass graft
surgery. Suspected infarctions were adjudicated by a Clinical
Events Committee in blinded manner, and serial cardiac
enzyme testing was mandated for all prolonged anginal
episodes and revascularization procedures.
The primary safety end point was bleeding. Bleeding was
classified as mild, moderate, severe or life-threatening,
based on the Global Utilization of Streptokinase and TPA
for Occluded arteries (GUSTO) scale (10), and as major or
minor, based on the Thrombolysis In Myocardial Infarction
(TIMI) scale (11).
In total, 10,948 patients from 726 participating hospitals
in 28 countries were randomized between November 1995
and January 1997. Of the 9,461 patients in the two primary
treatment arms, 2,438 were enrolled at 153 hospitals that
transferred at least one patient to a tertiary referral center
during study drug infusion. Of these patients, 429 were
transferred during the study drug infusion (“transfer pa-
tients”); 464 were transferred after completion of the study
drug; 1,534 completed the study drug infusion or their
hospital course at the enrolling facility; and 11 had un-
known transfer status and were therefore excluded from the
analysis (Fig. 1). For the purposes of this study, which
evaluated the relative efficacy of eptifibatide on clinical
outcomes at centers employing a strategy of early transfer,
we assumed that patients transferred after study drug
termination had much less risk of adverse events than those
transferred earlier. In addition, we predicted no continued
benefit of drug therapy after discontinuation (12). The 464
patients transferred after study drug termination were there-
fore considered as the “nontransfer” group.
Descriptive statistics. The patients’ baseline demographic
and clinical characteristics were collected from case report
form data and summarized for both transfer and nontransfer
groups. The baseline variables of both groups were also
stratified by randomized therapy (eptifibatide vs. placebo).
Continuous variables are presented as the median value
(interquartile range). For dichotomous variables, actual
percentile values are expressed. Comparisons between trans-
fer and nontransfer groups and between treatment groups
were conducted by using either a conventional chi-square
test or the Fisher exact test for dichotomous variables, and
the Wilcoxon rank-sum test for continuous variables.
Statistical modeling. Because hospital transfer was not a
randomized event, transfer and nontransfer groups may
possess unequal distributions of known predictors for death
and MI. We attempted to control for differences between
the groups by using an established model of 30-day death or
MI developed from the entire PURSUIT population (13).
Significant predictors of death or MI in this population,
among others, included age, gender, region of enrollment,
the presence of ST segment depression on the ECG at
enrollment and the presence of MI at enrollment. The
primary outcome was analyzed both before and after adjust-
ment for differences in the baseline variables between the
Abbreviations and Acronyms
ACS 5 acute coronary syndromes
CK-MB 5 creatine kinase, myocardial band
ECG 5 electrocardiogram or electrocardiographic
GP 5 glycoprotein
GUSTO 5 Global Utilization of Streptokinase and
TPA for Occluded arteries trial
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
PURSUIT 5 Platelet glycoprotein IIb/IIIa in unstable
angina: Receptor Suppression Using
Integrilin Therapy trial
TIMI 5 Thrombolysis In Myocardial Infarction
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transfer and nontransfer groups. To lessen the bias, all
nontransfer patients who died before the median time of
hospital transfer (two days) were also excluded from the
analysis (n 5 11 [8 received placebo, 3 received eptifi-
batide]) (Fig. 1).
To test for the differential effect of eptifibatide treatment
between the two groups, the interaction between transfer
status and randomized treatment was sampled and tested for
statistical significance using logistic regression analysis. The
results are also displayed as odds ratios (95% confidence
intervals) from logistic models (to compare the relative
treatment differences of eptifibatide in nontransfer and
transfer patients).
RESULTS
Table 1 displays the baseline characteristics of the 2,416
patients. A higher proportion of transfers occurred in North
America as compared with other regions, and a history of
PCI was associated with transfer. Fewer transfer patients
had a history of congestive heart failure, and there was a
trend toward transferring a higher percentage of patients
with MIs at enrollment compared with unstable angina. For
both the transfer and nontransfer groups, the baseline
characteristics were similar for those randomized to eptifi-
batide and those randomized to placebo.
Figure 2 displays the relationship between randomized
therapy and transfer status. Patients randomized to and
receiving eptifibatide were less frequently transferred than
those receiving placebo. Of the patients transferred, the
median time to transfer was two days (range 1 to 3) from
randomization, with no significant difference in the time to
transfer between those receiving eptifibatide and those
receiving placebo. The median time to transfer in the 464
patients (23%) transferred after study drug termination was
seven days (range 5 to 12) after randomization. Fifty-six
percent of the patients had the study drug discontinued
before or on the day of transfer, whereas 44% had therapy
continued for a median of one additional day (range 1 to 2).
Transfer patients underwent more angiography and revas-
cularization as compared with nontransfer patients; the
majority of these procedures (83%) occurred on the day of or
after transfer (Table 1).
Table 2 shows the unadjusted 30-day incidence of death
or MI by transfer status and by treatment with eptifibatide.
Regardless of randomized therapy and the timing of events,
the 30-day incidence of death or MI was greater in transfer
patients than in nontransfer patients (p 5 0.001). Eptifi-
batide was associated with a reduction in death or MI in
both transfer and nontransfer patients, with a greater
reduction in the composite end point in transfer patients as
compared with nontransfer patients. The greater absolute
reduction in death or MI seen in transfer patients as
compared with nontransfer patients was not statistically
different after adjustment for differences in baseline variables
between the two groups (p 5 0.54). Figure 3 displays the
Figure 1. Transfer group assignment.
Table 1. Clinical Characteristics by Transfer Status
Nontransfer
Patients
(n 5 1,987)
Transfer
Patients
(n 5 429)
Male patients (%) 66 66
Caucasian (%) 87 89
Age in years (25th, 75th) 64 (55, 72) 64 (55, 71)
North America (%) 42 77*
Hypertension (%) 52 53
Diabetes (%) 20 23
Previous stroke (%) 4 3
Previous infarction (%) 31 29
Previous heart failure (%) 11 5*
Previous angioplasty (%) 11 15*
Previous bypass surgery (%) 12 11
ST segment depression (%) 37 35
Rales (%) 9 8
MI at enrollment (%) 42 46
In-hospital procedures (%)
Angiography 59 94*
Angioplasty 18 46*
Bypass surgery 11 33*
*p , 0.05.
MI 5 myocardial infarction.
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relative 30-day benefits of eptifibatide as compared with
placebo in both transfer and nontransfer patients.
Eptifibatide showed a trend toward reducing the 30-day
incidence of death or MI, whether the study drug was
discontinued before or on the day of transfer (19.1% vs.
24.4%, p 5 0.321) or continued (16.0% vs. 22.3%, p 5
0.288). However, the benefit of eptifibatide was significantly
greater in those who continued the study drug (p 5 0.04).
Figure 4 and Table 3 display the cumulative incidence and
relative timing of death or MI, respectively, between trans-
fer and nontransfer patients randomized to eptifibatide or
placebo. Among transfer patients, the majority of benefit
from eptifibatide was seen before and on the day of transfer.
There were more bleeding events in transfer patients
(Table 4). However, the incidence of severe or life-
threatening bleeding was not different, nor was there any
significant difference in the incidence of stroke. Further-
more, among transfer patients, there was no significant
difference in the incidence of bleeding or stroke between
those randomized to eptifibatide and those receiving pla-
cebo.
DISCUSSION
This study, evaluating GP IIb/IIIa inhibition in patients
with non-ST segment ACS presenting to community hos-
pitals, where the decision to transfer rested with the treating
physician, introduces valuable information for treating pa-
tients in this setting. First, eptifibatide significantly reduced
the frequency of hospital transfer. Second, transfer patients,
in general, represent a group at high risk for adverse events.
Finally, eptifibatide use surrounding transfer was associated
with a reduction in death or MI through 30 days.
Patients are transferred from community hospitals to
tertiary referral centers after admission with ACS for
many reasons, ranging from elective transfers for procedures
to urgent transfers for worsening clinical conditions. In
PURSUIT, the decision to transfer patients was not a
randomized event; many clinical factors influenced the
decision. Although this type of study precludes direct
evaluation of the reason for transfer, physicians had no
knowledge of the GP IIb/IIIa therapy during this period,
and significantly less patients receiving eptifibatide were
transferred.
There has been much discussion regarding the role of GP
IIb/IIIa inhibitors in the passivation of the coagulation
cascade and stabilization of the ruptured plaque during ACS
(14). Eptifibatide may have altered the clinical course of
patients enough that physicians caring for the patients were
less inclined to transfer those patients. As evidence mounts
suggesting the benefits of reserving revascularization for
Figure 2. Relation between randomization to eptifibatide and transfer.
Table 2. Unadjusted 30-Day Death or Myocardial Infarction by Transfer Status and
Randomized Treatment
n
Overall
(%)
Placebo
(%)
Eptifibatide
(%)
AR
(%)
RR
(%)
p
Value
All patients 2,416 13.4 14.6 12.1 2.5 17.1 0.07
Nontransfer patients 1,987 11.7 12.5 11.0 1.5 12.0 0.30
Transfer patients 429 21.0 23.4 17.9 5.5 23.5 0.16
AR 5 absolute reduction; RR 5 relative reduction.
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those who cannot be medically stabilized (15–17), GP
IIb/IIIa antagonism may prove integral in the initial man-
agement of patients with ACS in community hospitals.
Furthermore, as health care resources become scarce and
insistence on the stringent justification of expenses becomes
more commonplace, preventing transfer and subsequent
procedures with GP IIb/IIIa inhibition may also prove
cost-effective.
Despite adjustment for differences in baseline variables
between transfer and nontransfer patients, death or MI
occurred more frequently in transfer patients than in pa-
tients admitted to those same centers and in those not
transferred while on the study drug (21% vs. 12%), as well
as in patients who remained at the site where they were
enrolled in the overall trial (15%) (8). This suggests that
transfer patients represent a higher risk group with recurrent
ischemia or more apt to have major adverse events. These
events were not solely related to revascularization proce-
dures: of the 62 end point MIs occurring after transfer, 40%
occurred far after the procedures. We also observed a
slightly greater reduction in 30-day events with eptifibatide
in transfer patients compared with nontransfer patients,
suggesting an augmented benefit of GP IIb/IIIa blockade in
patients with increased risk of short-term complications.
In this analysis, the 464 patients who were transferred
after study drug termination were included in the nontrans-
fer group. We considered the patients transferred after study
drug termination from centers concomitantly transferring
patients during study drug infusion to represent a dissimilar
group, and one at lesser risk for adverse events than the
group of patients transferred during study drug infusion.
Compared with patients transferred during study drug
infusion, late transfers experienced an overall lower rate of
death or MI at 30 days (21.0% vs. 17.2%). Nonetheless, the
unexpected finding of a reduced need for transfer associated
with eptifibatide persists when all transfers are combined
(34% vs. 40%, p 5 0.005) and when centers originally
excluded for only transferring patients after study drug
termination are included (22% vs. 26%, p 5 0.006). As no
continued accrual of benefit would be expected after termi-
nation of GP IIb/IIIa inhibition, some dilution of the
treatment effect with eptifibatide is observed (3.2% vs. 5.5%
absolute reduction) when all transfers are analyzed together,
possibly due to late procedures in these patients without GP
IIb/IIIa coverage. However, a reduction in events with
eptifibatide is still apparent, and a small benefit is seen, even
in an analysis of only those 464 patients who were trans-
ferred after study drug termination (0.8% absolute reduc-
tion). Our findings suggest that transfer, whether planned
or urgent, should be carried out while drug infusion is still
ongoing.
In this study, the benefits of administration of eptifibatide
by community hospitals before transfer came with no
additional risk of serious adverse bleeding. The similar
bleeding and stroke rates between those receiving eptifi-
batide and those receiving placebo occurred despite the high
risk demographic data of those transferred and the high
rates of invasive procedures after transfer.
To the best of our knowledge, this is the first known
evaluation of the strategy of transfer from community
hospitals to tertiary centers after patients were admitted for
non-ST segment elevation ACS. In our study, transfer to
tertiary centers was associated with more procedures and
more adverse events. In studies of ST segment elevation
acute MI, patients admitted to centers with on-site cathe-
terization facilities similarly undergo angiography and re-
vascularization more frequently than those admitted to
centers without catheterization facilities, but with no dif-
ference in mortality at three years of follow-up (18). In
retrospective comparisons of clinical outcomes between
patients with acute MI transferred to tertiary centers for
direct angioplasty and matched subjects who arrive directly
to these centers, greater enzymatic infarct size and lower
six-month ejection fractions are seen in those transferred,
but again with no differences in six-month mortality
(19,20). The clinical outcomes associated with transfer in
our study are consistent with evaluations of multidisci-
plinary transfers from acute-care hospitals to tertiary centers
in general, where higher mortality (.50% relative increases)
is common despite adjustment for differences in disease
severity (21,22).
Study limitations. Certain limitations must be taken into
consideration when interpreting this study. Indications
for transfer, and the practice thereof, were not addressed
in the PURSUIT protocol. Eptifibatide was therefore not
randomly assigned based on transfer status, and was admin-
istered in subgroups with unequal baseline characteristics.
Although we adjusted for some of these variables, unrecog-
nized confounders could contribute to the observed differ-
ences in event rates. Furthermore, transfer was a postran-
domization event, possibly affected by study drug
assignment or clinical events. Although some of these
Figure 3. Cox proportional odds ratios displaying the relative benefit of
eptifibatide as compared with placebo in transfer and nontransfer patients.
Squares represent point estimates; lines represent 95% confidence inter-
vals.
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events were captured on case report forms, there is no model
incorporating postrandomization events that predicts 30-
day outcomes. Should one exist, uncollected postrandom-
ization events would still confound the conclusions.
Another limitation of our study involves the definition of
transfer groups. As we sought to evaluate a therapy initiated
shortly after presentation, follow-up began at randomiza-
tion. Although deaths before the median time to transfer
were censored, pretransfer MIs were not. We chose not to
exclude these MIs, because the effect of eptifibatide on transfer
rates may be mediated through an effect on early MI. This
study design allowed events that may have contributed to the
decision to transfer to be included in the analysis, and it mimics
commonly used clinical care strategies.
Conclusions. Eptifibatide use at community hospitals early
after presentation with non-ST segment elevation ACS
Figure 4. Kaplan-Meier plots displaying death or myocardial infarction from randomization to 30 days by treatment assignment between patients
transferred during study drug infusion (A) and nontransfer patients (B). Vertical lines represent the 25th, 75th median times to transfer.
Table 3. Incidence and Timing of 30-Day Death or Myocardial Infarction in Transfer Patients
Overall
(n 5 429)
Placebo
(n 5 239)
Eptifibatide
(n 5 190) AR RR
Before transfer 9 (2.1%) 6 (2.5%) 3 (1.6%) 0.9% 36%
Day of transfer 33 (7.7%) 23 (9.6%) 10 (5.3%) 6.1% 64%
After transfer 48 (11.2%) 27 (11.3%) 21 (11.1%) 0.2% 1.7%
AR 5 absolute reduction; RR 5 relative reduction.
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reduces the need for transfer and improves clinical outcomes
in those who require transfer and in those remaining at the
community hospital. Transfer, if necessary, should be per-
formed in conjunction with continued GP IIb/IIIa inhibi-
tion, based on either the patient’s high risk profile or the
likelihood of subsequent revascularization.
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